Skip to main content

Innate Pharma SA

IPHA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001598599

No open-market purchases or sales by Innate Pharma SA insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $354.0K in total; no superinvestor holds it.

Other share classesIPHYF

13F holders, Q2 2026

Institutional positions in Innate Pharma SA as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
10
+1 vs. Q1 2026
Shares held
192.4K
+8.47K (+4.6%) vs. Q1 2026
Total value
$354.0K
+$118.6K (+50.4%) vs. Q1 2026
New holders
3
2 more added
Sold out
2
3 more reduced

Compare with Q1 2026: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting IPHA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2026: 10 institutions
Q1 2021: 7 institutionsQ2 2021: 5 institutionsQ3 2021: 18 institutionsQ4 2021: 16 institutionsQ1 2022: 13 institutionsQ2 2022: 13 institutionsQ3 2022: 12 institutionsQ4 2022: 11 institutionsQ1 2023: 9 institutionsQ2 2023: 9 institutionsQ3 2023: 8 institutionsQ4 2023: 8 institutionsQ1 2024: 9 institutionsQ2 2024: 8 institutionsQ3 2024: 8 institutionsQ4 2024: 9 institutionsQ1 2025: 10 institutionsQ2 2025: 9 institutionsQ3 2025: 9 institutionsQ4 2025: 11 institutionsQ1 2026: 9 institutionsQ2 2026: 10 institutions
Value heldQ2 2026: $354.0K
Q1 2021: $762.6KQ2 2021: $296.0KQ3 2021: $5.82MQ4 2021: $6.52MQ1 2022: $3.20MQ2 2022: $2.58MQ3 2022: $1.89MQ4 2022: $1.49MQ1 2023: $1.13MQ2 2023: $735.6KQ3 2023: $805.6KQ4 2023: $490.7KQ1 2024: $985.4KQ2 2024: $469.0KQ3 2024: $545.1KQ4 2024: $254.8KQ1 2025: $281.6KQ2 2025: $178.7KQ3 2025: $157.9KQ4 2025: $483.5KQ1 2026: $235.5KQ2 2026: $354.0K
Institutions holding IPHA and their total value by quarter
QuarterHoldersValue
Q2 202610$354.0K
Q1 20269$235.5K
Q4 202511$483.5K
Q3 20259$157.9K
Q2 20259$178.7K
Q1 202510$281.6K
Q4 20249$254.8K
Q3 20248$545.1K
Q2 20248$469.0K
Q1 20249$985.4K
Q4 20238$490.7K
Q3 20238$805.6K
Q2 20239$735.6K
Q1 20239$1.13M
Q4 202211$1.49M
Q3 202212$1.89M
Q2 202213$2.58M
Q1 202213$3.20M
Q4 202116$6.52M
Q3 202118$5.82M
Q2 20215$296.0K
Q1 20217$762.6K

Institutions, Q2 2026

Shares, value and share of portfolio for each institution holding Innate Pharma SA; share changes are against Q1 2026.

Institutions holding IPHA in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Lion Point Capital, LP81,151$149.3K0.71%00.0%Unchanged
Morgan Stanley43,524$80.1K0.00%00.0%Unchanged
SmartHarvest Portfolios, LLC23,750$43.7K0.01%+23,750New
XTX Topco Ltd15,130$27.8K0.00%+15,130New
Citadel Advisors LLC12,441$22.9K0.00%+12,441New
Jane Street Group, LLC10,310$19.0K0.00%−33,055−76.2%Reduced
Rhumbline Advisers4,719$8.68K0.00%−15−0.3%Reduced
UBS Group AG1,363$2.51K0.00%+502+58.3%Added
Farther Finance Advisors, LLC21$380.00%+11+110.0%Added
GAMMA Investing LLC9$170.00%−231−96.3%Reduced
Millennium Management LLC0$00.00%−10,064−100.0%Sold out
Caitong International Asset Management Co., Ltd0$00.00%−2−100.0%Sold out